Figure 2.
Mean difference (MD) of total anti-SARS-CoV-2 RBD antibodies in seronegative subjects receiving a complete cycle (i.e., two doses) of Pfizer COVID-19 mRNA BNT162b2 vaccine as calculated after 21 and 50 days from the first dose.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.